Repligen Corporation heads into its May 14 Q1 earnings with shorts rebuilding from their April peak and a notable divergence opening up between the options market's easing caution and still-elevated bearish positioning in the stock loan market.
Short interest has climbed meaningfully over the past six weeks. SI as a percentage of free float is now 10.1%, up from roughly 8.3% at the end of March — a rise of nearly two percentage points in six weeks that puts shorts near the top of their recent range. The peak came in mid-April at 11.2% before a partial unwind; the current level represents a modest rebuilding from the post-earnings dip. At 7.0 days to cover per the latest FINRA data, covering would take the better part of two trading weeks — meaningful friction for anyone caught offside by a strong print.
The borrow market, however, tells a more relaxed story. Cost to borrow is running at just 0.59%, elevated only slightly from its recent range and nowhere near the levels that signal genuine squeeze pressure. Availability is not tight. The lending pool remains largely open, suggesting that while shorts have added size over the past month, the demand for borrows has not overwhelmed supply. Options positioning has similarly cooled. The put/call ratio of 1.08 is running slightly below its 20-day average of 1.14 — not bullish, but materially less fearful than the defensive readings of 1.35 and above that characterised mid-April and late March. Whatever hedging pressure built up into the April period appears to have largely unwound as the stock rallied 7% over the past week to $125.61.
The Street remains constructive with caveats. Most analysts covering Repligen hold positive ratings, but the direction of target-price revisions through April was decidedly lower — multiple firms trimmed targets into the $140-$145 range amid uncertainty about margin delivery. That dynamic reversed sharply this week: Barclays raised its target to $160 while keeping its Overweight, fresh confirmation of the positive skew. The mean price target of $179.78 carries a 43% implied return to the current price — a gap that reflects both genuine fundamental optimism and the stock's own underperformance versus those targets. The bull case centres on bioprocessing recovery and Process Analytics franchise strength — growth there exceeded 50% year-on-year in the most recent period. Bears point to operating margin compression, with adjusted operating margin guided near 13.5%, and concentration risk if large-customer order volumes disappoint.
Institutional ownership tells a story of accumulation alongside the volatility. T. Rowe Price added over 1.1 million shares in Q1, the largest recent build among major holders, lifting its stake to 9.3% of shares outstanding. Wasatch Advisors and Franklin Resources also initiated or substantially built positions, while Citadel trimmed by roughly 290,000 shares. BlackRock, the largest holder at 11.7%, added nearly 480,000 shares through April. The net picture is one of active manager confidence absorbing shares that weaker hands let go during the April sell-off. The only notable insider transaction of recent weeks was a CEO sale of 3,832 shares at $140 on April 21 — a minor, likely routine disposal given the stock subsequently dipped below that level before recovering.
Peer performance adds useful context for what drove this week's move. IQV and RVTY — both highly correlated life-sciences tools names — surged 9.6% and 6.7% respectively on the day, suggesting a broad sector re-rating rather than a Repligen-specific catalyst. TMO was effectively flat on the week at -0.7%, while DHR slipped 2.4%. The dispersion within the group means Repligen's 7% weekly gain reflects both idiosyncratic momentum and a favourable tide for mid-sized tools names.
The setup into May 14 is therefore one of elevated but not extreme short interest, loosening borrow conditions, and a stock that has reclaimed a meaningful slice of its April losses — the central question for that print being whether margin guidance can credibly tighten while revenue growth holds.
See the live data behind this article on ORTEX.
Open RGEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
